Low-Molecular-Weight Heparin

Key Points

• To evaluate the efficacy and safety of low-molecular-weight heparin in preventing venous thromboembolism.
• Randomized trial design
• Compared low-molecular-weight heparin to standard anticoagulant treatment
• Analyzed clinical outcomes and safety profiles
• Demonstrated a significant reduction in thrombosis events (p<0.05) in the low-molecular-weight heparin group
• Found lower rates of adverse events compared to standard treatment
• Indicated improved quality of life metrics among patients treated with low-molecular-weight heparin